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Androgen withdrawal induces hypoxia in androgen-sensitive tissue; this is important as in the tumour microenvironment,
hypoxia is known to drive malignant progression. Our study examined the time-dependent effect of androgen deprivation
therapy (ADT) on tumour oxygenation and investigated the role of ADT-induced hypoxia on malignant progression in prostate
tumours. LNCaP xenografted tumours were treated with anti-androgens and tumour oxygenation measured. Dorsal skin fold
(DSF) chambers were used to image tumour vasculature in vivo. Quantitative PCR (QPCR) identified differential gene
expression following treatment with bicalutamide. Bicalutamide-treated and vehicle-only-treated tumours were re-established
in vitro, and invasion and sensitivity to docetaxel were measured. Tumour growth delay was calculated following treatment
with bicalutamide combined with the bioreductive drug AQ4N. Tumour oxygenation measurements showed a precipitate
decrease following initiation of ADT. A clinically relevant dose of bicalutamide (2 mg/kg/day) decreased tumour oxygenation
by 45% within 24 hr, reaching a nadir of 0.09% oxygen (0.67 6 0.06 mmHg) by Day 7; this persisted until Day 14 when it
increased up to Day 28. Using DSF chambers, LNCaP tumours treated with bicalutamide showed loss of small vessels at Days
7 and 14 with revascularisation occurring by Day 21. QPCR showed changes in gene expression consistent with the vascular
changes and malignant progression. Cells from bicalutamide-treated tumours were more malignant than vehicle-treated
controls. Combining bicalutamide with AQ4N (50 mg/kg, single dose) caused greater tumour growth delay than bicalutamide
alone. Our study shows that bicalutamide-induced hypoxia selects for cells that show malignant progression; targeting
hypoxic cells may provide greater clinical benefit.
Hypoxia is a common feature of solid tumours and has been
shown to drive malignant progression.1 Clinical studies have
indicated that higher levels of hypoxia predict for poor local
control and decreased disease free survival in patients with
cancer.2 This may be particularly important in prostate can-
cer as these tumours show one of the lowest mean oxygen
levels of any tumour type [2.4 mmHg; 0.32% oxygen partial
pressure (pO2)].
3 Indeed, increased hypoxia has been shown
to correlate with clinical staging4 and biochemical failure af-
ter radiotherapy in patients with prostate cancer.5,6 In addi-
tion, growing evidence supports the role of hypoxia in the
malignant progression of the disease.7–9
Androgen deprivation therapy (ADT) has been the main-
stay of treatment for locally advanced prostate cancer for
many years. Although this treatment is initially successful,
disease re-emergence occurs after a median of 18 months.10
This castrate-resistant form of the disease is more aggressive
and is ultimately fatal; however, recent advances have identi-
ﬁed approaches that have shown some improvements in
response.11 The reason for the inevitable relapse has yet to be
fully identiﬁed.
A number of laboratory studies have demonstrated that
androgen withdrawal via castration or use of anti-androgens
leads to a rapid decrease in blood ﬂow to the normal rat
prostate.12,13 This is also accompanied by a reduction in
microvessel density.14 Castration of mice bearing the andro-
gen-sensitive Shionogi tumour resulted in a reduction in the
number of tumour blood vessels15 and a decrease in tumour
oxygenation16 prior to tumour regression. A later rise in
tumour oxygen levels was associated with re-growth.
We have previously demonstrated that exposure of LNCaP
cells to cycles of hypoxia followed by reoxygenation leads to
development of cells with an aggressive phenotype character-
ised by greater invasion, decreased sensitivity to apoptosis and
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androgen independence.17 Our study investigates the physio-
logical effect of anti-androgens in prostate tumours in vivo,
with speciﬁc interest in tumour hypoxia. The study identiﬁes
the time-dependent effect of ADT on tumour vasculature and
oxygenation and strongly suggests that hypoxia may be the
underlying mechanism for driving malignant progression seen
in locally advanced prostate cancer after treatment with ADT.
Since we established that ADT results in profound and per-
sistent hypoxia in bicalutamide-treated tumours, we carried
out a pilot study to target these hypoxic cells using the biore-
ductive drug AQ4N (banoxantrone). We found that informed
scheduling of AQ4N in combination with bicalutamide
resulted in a greater tumour growth delay and reduced meta-
static spread than with treating with bicalutamide alone.
The results from these studies demonstrate that selection
of a targeting strategy based on longitudinal in vivo physio-
logical data can signiﬁcantly enhance the overall tumour
response to bicalutamide.
Material and Methods
Cell culture
Parental LNCaP cells (ATCC, Rockville, MD) and generated
sub-lines were maintained in RPMI-1640 medium supple-
mented with 10% foetal bovine serum, 10 mM HEPES and 5
mM glucose (all from Invitrogen, Paisley, UK). All experi-
ments were carried out at 37C under 5% CO2 in air.
Drug preparation and administration
Bicalutamide (Casodex; gift from AstraZeneca, Macclesﬁeld,
UK), ﬁnasteride (Sigma, Gillingham, UK) and ﬂutamide
(Sigma, Gillingham, UK) were prepared in vehicle (0.1% di-
methyl sulfoxide in corn oil) and administered orally (p.o.) at
the doses identiﬁed in Table 1. For all longitudinal studies,
vehicle or bicalutamide (2 mg/kg) was administered p.o.
daily; the dose of 2 mg/kg/day is equivalent to a 50-mg daily
tablet in men. AQ4N (banoxantrone; a gift from Oncotherics,
Shepsted, UK) was prepared in phosphate buffered saline
(PBS) and was administered as a single bolus intraperitoneal
injection (50 mg/kg).
In vivo models
All experiments were conducted in accordance with the Ani-
mal (Scientiﬁc Procedures) Act 1986 and the UKCCCR
Guidelines (2010) for the welfare of animals in experimental
neoplasia.18 LNCaP cells (5  106 in Matrigel) were
implanted on the rear dorsum of 8- to 10-week-old male
Balb/c SCID mice. When tumour volume was 150–200 mm3,
mice were randomly assigned to treatment groups.
Tumour oxygenation measurement. The pO2 of tumours was
recorded using an Oxylite 2000 system (Oxford Optronix,
Oxford, UK). Animals were secured into a bespoke restrain-
ing device with their tumours exposed. The ﬁbre optic probe
was inserted into a 21-gauge needle; this was placed into the
tumour tissue. The needle was withdrawn and the probe was
left to stabilise for 10 min before readings commenced.
Thereafter, pO2 values were recorded every 15 sec for 10
min. The readings were taken in two sites for each time
point; ﬁnal measures were an average of all readings.
Tumour growth delay. Tumour dimensions were measured
using calipers, and the geometric mean diameter (GMD) was
calculated using the following formula: GMD ¼ 3Hlength 
breadth  height. Tumour volume was calculated using the
following formula: 4/3pr3, where r ¼ GMD/2. Growth curves
were drawn, and the time to double the initial treatment
volume was calculated. Mice were treated as indicated in
Figure 5, and they were sacriﬁced at Day 28.
Dorsal skin fold model. This involved surgically implanting a
skin fold on the backs of 12-week-old Balb/c SCID mice as pre-
viously described.19 The specially designed window chamber
(APJ Trading, Ventura, CA) contains a viewing port into which
LNCaP tumour fragments were implanted on the exposed pan-
niculus carnosus muscle. Following replacement of the cover
slip and its securing with a c-clamp, the tumours were left for 7
days to vascularise. To assess changes in tumour vasculature,
animals were given an i.v. injection of 150-kDa FITC-labelled
dextran (50 ll, 50 mg/ml; Sigma, Gillingham, UK) 15 min prior
to imaging; the FITC signal was detected using a confocal
microscope (Leica, Solmes, Germany). Sequential images of the
implanted tumour fragments were taken at Day 0 and Days 7,
14 and 21 following treatment. For each time point, images were
taken from three sites on the tumour from ﬁve animals. Area
covered by vessels was calculated using Image J software (NIH,
Bethesda, MD). The results presented are an average6 SE.
Assessment of metastasis. Male Balb/c SCID mice were
implanted on the rear dorsum with luciferase-expressing
LNCaP cells. The luciferase-expressing cells had similar char-
acteristics to parental LNCaP cells (see Supporting Informa-
tion Fig. S1). On Day 28 of treatment, animals were injected
i.p. with a solution of D-luciferin (150 mg/kg in PBS) 15 min
prior to imaging. Animals were then killed and a range of
What’s new?
Standard androgen-deprivation therapy (ADT) can induce profound and persistent hypoxia within prostate-cancer tumors.
Unfortunately, hypoxia can actually result in more aggressive tumors in many types of cancer. In this study, the authors found
that combined treatment with ADT and the drug AQ4N (banoxantrone) improves primary tumor control and reduces metastatic
spread in a mouse xenograft model of prostate cancer. (In hypoxic conditions AQ4N is reduced to AQ4, a highly cytotoxic
compound.) These results provide proof of principle for targeting hypoxic cells in the treatment of prostate cancer.
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tissues were removed for the detection of bioluminescence
using the IVIS imaging system (Xenogen, Santa Clara, CA);
only the lungs showed bioluminescence. Images were taken
for 5 min, and quantiﬁcation of bioluminescence was
achieved by drawing a region of interest around the area and
measuring total ﬂux in photons/second (ph/sec). The results
shown are an average of ﬁve mice per treatment group.
Immunohistochemistry
Bicalutamide-treated (2 mg/kg, daily p.o.) and vehicle-only-
treated mice were culled on Day 0 and Days 7, 14, 21 or 28,
and the LNCaP tumours were removed and subsequently
ﬁxed in formalin (10%; Sigma, Gillingham, UK). Samples
were wax embedded, sectioned at 5 lm and dewaxed in xy-
lene. Following rehydration in a descending series of ethanol
followed by PBS washes, enzyme digestion was carried out
using 0.4% pepsin (Sigma, Gillingham, UK) in 0.01 M HCl
(pH 2.5) for 30 min. Endogenous peroxidases were blocked
using 3% hydrogen peroxide, and non-speciﬁc antibody bind-
ing was blocked using 1% bovine serum albumin (BSA). Sec-
tions were incubated with Glut1 primary antibody (1:400;
Abcam, Cambridge, UK); BSA alone was used as a negative
control. Sections were incubated with HRP-labelled secondary
goat antibody (1:200; Abcam, Cambridge, UK), and staining
was visualised using 3,30-diaminobenzidine solution (Sigma,
Gillingham, UK). Haemotoxylin was used as a counterstain.
Scoring of the extent and intensity of staining was carried
out in ﬁve ﬁelds of view per section using a light microscope
at a ﬁnal magniﬁcation of 200. A total of two slides per
tumour and ﬁve individual tumours per treatment group
were quantiﬁed. The area of staining was assigned a value: 0–
5% ¼ 0; 6–25% ¼ 1; 26–75% ¼ 2 and >75% ¼ 3. Intensity
of staining assigned a value, none ¼ 0; light ¼ 1; medium ¼
2 and dark ¼ 3, and added to the score for area of staining.
Each section was scored in a blind manner by two independ-
ent observers, and the results were averaged. Inter-observer
difference was <10%.
Gene expression analysis
Bicalutamide-treated (2 mg/kg, daily p.o.) and vehicle-only
treated animals were culled at Day 0 and Days 7, 14, 21 and 28.
Total RNA was extracted from tumour tissue using Trizol reagent
(Invitrogen, Paisley, UK) according to the manufacturer’s instruc-
tions. An aliquot containing 2 lg of RNA was reverse transcribed
with RevertAidTM reagent (Fermentas, Cambridge, UK) accord-
ing to the manufacturer’s instructions. The Lightcycler 480 system
(Roche, Welwyn Garden City, UK) was used to perform quantita-
tive PCR (QPCR) with MaximaTM Sybr green reagents (Fermen-
tas Cambridge, UK) under the following conditions: 95C for 2
min followed by 40 cycles of 95C for 15 sec, 60 for 30 sec and
72 for 30 sec. In three independent experiments, three tumour
samples were pooled giving a total of nine tumour samples. Each
pooled sample was analysed in duplicate. Primer sets used for the
study can be found in Supporting Information Figure S2.
Western blotting
Protein was extracted from tumour samples using a ProteoJETTM
protein extraction kit (Fermentas, Cambridge, UK). A total of 60
lg of protein was electrophoresed on a 10% SDS-PAGE gel,
transferred to polyvinylidene diﬂuoride membrane (Millipore,
Watford, UK) and probed with the primary antibody at the
appropriate dilution: androgen receptor (AR) (1:1,000; Millipore,
Watford, UK), interleukin 8 (IL-8) (1:1,000; AbD Serotec,
Kidlington, UK), vascular endothelial growth factor (VEGF)
(1:500; Santa Cruz, CA) and glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) (1:5,000; Cell Signaling, Beverley, MA). The
levels of protein were measured using Supersignal Pico Chemilu-
minescent substrate (Pierce, Northumberland, UK) and Quantity
One analysis software (BioRad, Bath, UK).
Establishment of LNCaP-B1 and V1 sub-lines
The LNCaP tumours treated in vivo with either bicalutamide
(2 mg/kg/day; LNCaP-B1) or vehicle-only (LNCaP-V1) for 28
days were excised, homogenised and digested to produce a sin-
gle cell suspension. These were then re-established in vitro
using the same culture conditions as parental LNCaP cells.
Cell doubling times
Population doubling times were calculated following the use of
the trypan blue exclusion assay on cell cultures. In brief, 35-mm
dishes were plated with 2  105 ex vivo cultured cells, which
were then incubated at 37C in an atmosphere containing 5%
CO2 in air. At 24, 48, 72 and 96 hr after plating, adherent cells
were trypsinised, stained with trypan blue and counted. Dou-
bling times were calculated using the following formula: N/N0 ¼
ekt, where N is the cell number at time t, N0 is the initial cell
number (Time 0) and k is a constant. The k value was calculated
for each time point between 24 and 96 hr, and an average value
was used to calculate the time t when N/N0 ¼ 2.
In vitro cell invasion assay
The capacity of LNCaP-B1 and LNCaP-V1 tumour cells to
invade through Matrigel was determined using a cell invasion
Table 1. Oxygenation of LNCaP tumour xenografts 24 hr after
exposure to androgen deprivation therapy
Treatment
Drug
dose
(mg/kg)
Mean pO2
value
(mmHg)
p-value
(compared to
zero time point)
None (zero time) 0 6.05 6 0.57
Vehicle 0 5.7 6 0.86 0.49
Finasteride 50 5.50 6 0.76 0.67
Flutamide 10 2.65 6 0.32 0.007
Flutamide 25 0.97 6 0.14 0.002
Bicalutamide 2 2.92 6 0.33 0.006
Bicalutamide 10 0.73 6 0.12 0.002
Male SCID mice bearing tumours of 150–200 mm2 were assigned to
the treatment groups indicated. Oxygen measurements were made
before and 24 hr after treatment using an Oxylite oxygen-sensing fibre
optic probe. Data shown are the mean 6 SE (n ¼ 5). The p-values
were calculated using a two-tailed t-test.
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assay kit (Chemicon, Chandlers Ford, UK) according to the
manufacturer’s instructions. Brieﬂy, cells were allowed to
invade towards a chemical stimulus for 72 hr, and then
invading cells were stained with crystal violet and counted.
The results are an average of three independent experiments
6 SE.
XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide) assay
The viability of LNCaP-B1 and LNCaP-V1 tumour cells fol-
lowing treatment with docetaxel was measured using an XTT
assay kit (Roche, Welwyn Garden City, UK). Brieﬂy, cells
were plated at 1  104 into individual wells of a 96-well plate
and left to adhere overnight. Docetaxel (ﬁnal concentration
of 100 nM) was added, and then the cells were incubated for
a further 48 hr. A 50-ll aliquot of XTT solution was added
to each well, and the plate was returned to the incubator for
3 hr at 37C. The absorbance of each well was measured at
494 nm using a Fluorostar Omega plate reader (BMG Lab-
tech, Aylesbury, UK). Viability was expressed as the mean 6
SE percentage of the untreated controls from three independ-
ent experiments.
siRNA transfection
The appropriate number of cells were plated in antibiotic-
free medium 16 hr prior to transfection. All materials for
siRNA transfection were obtained from Santa Cruz, Beverley,
MA, and used according to the manufacturer’s instructions.
siRNA control samples contained a scrambled sequence that
does not lead to speciﬁc degradation of any known cellular
mRNA; this was used as a negative control.
Statistical analysis
Comparisons between datasets from in vitro QPCR analysis,
in vivo oxygenation of tumour xenografts (Table 1), tumour
growth delay and quantiﬁcation of bioluminescence were car-
ried out using a two-tailed t-test. All other datasets were ana-
lysed using a two-way ANOVA with post hoc Bonferroni
analysis. All statistical analyses were carried out using Prism
5.0.
Results
Interference with androgen signalling causes a decrease in
tumour pO2 levels
LNCaP tumour-bearing mice were treated with three drugs
that reduce the effects of androgens on tumours, and intra-
tumour pO2 levels were measured both before and after 24
hr of treatment. Tumours had a pO2 value of 6.05 6
0.57 mmHg before treatment (Table 1). Small but non-signif-
icant changes in pO2 levels were observed in tumours treated
with vehicle-only (p ¼ 0.49) or ﬁnasteride (p ¼ 0.67). Treat-
ment with ﬂutamide resulted in a signiﬁcant decrease in
tumour pO2 at both 10 mg/kg (2.65 6 0.32 mmHg) and 25
mg/kg (0.97 6 0.14 mmHg). Bicalutamide also caused a sig-
niﬁcant drop in pO2 using either 10 mg/kg (0.73 6 0.12
mmHg) or the more clinically relevant dose of 2 mg/kg
(2.92 6 0.33 mmHg) within 24 hr of treatment.
Bicalutamide alters LNCaP tumour pO2 levels in a time-
dependent manner
The pO2 of LNCaP tumours was measured longitudinally from
Day 0 to Day 28 in individual tumours. Initial tumour pO2 read-
ings in vehicle-treated (5.85 mmHg) and bicalutamide-treated
(5.75 mmHg) groups were similar (p ¼ 0.31), and this remained
constant in the vehicle-treated animals for the duration of the
study (Fig. 1a). However, daily bicalutamide (2 mg/kg, p.o.)
caused an immediate and profound decrease in tumour pO2.
This dropped by 45% of pre-treatment values within the ﬁrst 24
hr, and then the levels continued to fall precipitously; by Day 7,
pO2 values were approximately tenfold less than at Day 0, that
is, 0.09% oxygen (0.67 6 0.06 mmHg). Figure 1b illustrates this
fall with a dramatic shift in the relative frequency distribution of
oxygen within these tumours. This nadir persisted until at least
Day 14 (0.65 6 0.06 mmHg) after treatment; however, by Day
17, oxygenation began to increase and gradually rose until the
end of the study despite the continuation of daily bicalutamide
treatment (Fig. 1a).
Glut1 staining was used to conﬁrm the presence of hy-
poxia during treatment with bicalutamide. Weak Glut1 stain-
ing was observed in tumour samples before treatment; this
level was maintained in all vehicle-treated tumours through-
out the study (Fig. 1c). Using a semi-quantitative method to
score Glut1 staining, no signiﬁcant change was observed
throughout the study in vehicle-treated tumours (p  0.05 in
all cases; Fig. 1d). In bicalutamide-treated tumours, the inten-
sity and area of staining changed along the time course (Figs.
1c and 1d). After 7 and 14 days of treatment, large areas of
dark staining were observed; this was signiﬁcantly different
from that observed in vehicle-treated tumours. On Days 21
and 28, the semi-quantitative measurement of Glut1 staining
in sections from bicalutamide-treated tumours was not signiﬁ-
cantly different than that observed in vehicle-treated tumours.
Bicalutamide alters the number of tumour microvessels
in a time-dependent manner
LNCaP tumour fragments were implanted into the dorsal skin
fold (DSF) of Balb/c SCID mice and allowed to vascularise for
7 days; at this time (designated as treatment day 0), the
tumours were well vascularised (Fig. 2a). When tumours were
treated with vehicle, the vascular network was maintained
throughout the experiment (21 days). However, after 7 days of
treatment with bicalutamide (2 mg/kg/day), loss of small blood
vessels was observed, which was more pronounced by Day 14.
After 21 days of bicalutamide treatment, the larger vessels
were still prominent; however, many smaller vessels were re-
established and small sprouting vessels can be seen.
The surface area covered by blood vessels was analysed for
each time point during treatment (Fig. 2b). Initial coverage by
blood vessels was similar in both vehicle-treated (3.3  103
lM2) and bicalutamide-treated (3.0  103 lM2) tumours. In
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vehicle-treated animals, a typical vascular pattern was observed
with the proportion of tumour area covered by vessels rising
gradually throughout the course of the experiment. However,
after 7 days, bicalutamide treatment coverage was 1.6  103
lM2 compared to 3.8  103 lM2 in vehicle-treated tumours (p
 0.05). This surface area was maintained following 14 days
bicalutamide treatment compared to 5.2  103 lM2 in vehicle-
treated tumours (p  0.01); the vessels that remained were
mainly large vessels with very few smaller capillaries. Following
21 days of bicalutamide treatment, the area covered by blood
vessels had risen to 4.8  103 lM2; however, this was still sig-
niﬁcantly different from the control tumours (p  0.05).
Gene expression profiles change over time in
bicalutamide-treated tumours
QPCR was used to assess the effect of bicalutamide-induced
hypoxia on the expression of a selection of genes involved
with angiogenesis and prostate tumour malignant progres-
sion. From Day 14 of bicalutamide treatment, tumour-associ-
ated androgen receptor levels were higher than in those
treated with vehicle-only; however, these did not reach statis-
tical signiﬁcance (Fig. 3a).
The expression of the pro-angiogenic VEGF mRNA fol-
lowed the pattern of blood vessel density in the DSF model
with levels decreasing signiﬁcantly after 7 days of bicaluta-
mide treatment (Fig. 3b). Maximal expression was observed
at 21 days of bicalutamide treatment with VEGF mRNA lev-
els 2.5-fold higher than in vehicle-only controls.
IL-8 mRNA expression in vehicle-treated tumours
increased slightly during the study. In bicalutamide-treated
samples, IL-8 mRNA expression was signiﬁcantly less than in
vehicle-treated controls at Day 14 (Fig. 3c). By Day 21, IL-8
mRNA expression in bicalutamide-treated tumours had risen
very signiﬁcantly to 3.9-fold higher than Day 0 controls (p 
0.001); this corresponded to the angiogenic burst observed in
the DSF.
Bcl-2 mRNA levels decreased signiﬁcantly in bicaluta-
mide-treated tumours after 7 days (Fig. 3d). By 21 days of
bicalutamide treatment, Bcl-2 mRNA was 2.9-fold higher
than in vehicle-treated tumours (p  0.001). Although Bcl-2
mRNA levels in bicalutamide-treated tumours were slightly
reduced at Day 28, they were still signiﬁcantly higher than in
vehicle-treated tumours (p  0.01).
Bicalutamide treatment in vivo selects for
LNCaP cells with an aggressive phenotype
Tumour tissue was excised from mice treated for 28 days with
either vehicle-only (LNCaP-V1) or bicalutamide (2 mg/kg/day)
Figure 1. Changes in pO2 levels in LNCaP tumour xenografts during daily bicalutamide treatment. Male Balb/c SCID mice bearing tumours
of 150–200 mm2 were used. (a) Oxylite electrode measurements of pO2 levels in both vehicle-treated and bicalutamide-treated (2 mg/kg)
LNCaP tumours were taken on the indicated days. The results shown are mean 6 SE (n ¼ 10). (b) Representative histograms of the relative
frequency of pO2 measurements of LNCaP tumours treated with (i) vehicle and (ii) bicalutamide after 7 days of treatment. (c) Glut1 staining
of LNCaP tumour xenografts treated with vehicle and bicalutamide (magnification: 20). (d) Semi-quantitative analysis of Glut1 staining in
LNCaP tumours during bicalutamide treatment. The results shown are mean 6 SE (n ¼ 5); *p  0.05 (two-way ANOVA).
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(LNCaP-B1). The cells were re-established in vitro, and the
population doubling times were assessed using the trypan
blue exclusion assay. Both cell lines had similar doubling
times in normal culture medium (36.1 6 6.1 hr for LNCaP-
B1 and 37.8 6 5.6 hr for LNCaP-V1); however, in charcoal-
stripped medium (which removes androgenic growth factors),
the doubling times were signiﬁcantly different (43.0 6 2.2 hr
for LNCaP-B1 and 50.2 6 3.4 hr for LNCaP-V1; p ¼ 0.033).
The protein and mRNA levels of a number of genes asso-
ciated with malignant progression were assessed in the cell
lines (Figs. 4a and 4b). The levels of the pro-apoptotic Bax
protein and mRNA were reduced in the LNCaP-B1 sub-line;
conversely, mRNA and protein levels of the anti-apoptotic
Bcl-2 were increased twofold. The levels of IL-8 and AR were
3.6- and 1.8-fold higher in LNCaP-B1 cells compared to
LNCaP-V1s.
Cell viability after treatment with docetaxel (100 nM) was
assessed using the XTT assay. A signiﬁcant increase in viabil-
ity was observed in LNCaP-B1 compared to LNCaP-V1 cells
(Fig. 4c). Treating the LNCaP-B1 cells with siRNA-targeting
Bcl-2 tested the role of increased Bcl-2 in the observed resist-
ance to docetaxel. Sensitivity to docetaxel increased (Fig. 4c)
after Bcl-2 siRNA reduced Bcl-2 expression by 80% (Fig. 4d).
As increased invasion is a hallmark of more malignant cells,
the invasive capacity of LNCaP-B1 and LNCaP-V1 cells was
compared using an in vitro assay. More LNCaP-B1 cells
invaded through the MatrigelV
R
membrane than LNCaP-V1
cells (p  0.001; Fig. 4e). To assess the role of IL-8 in the
increased invasion, LNCaP-B1 cells were treated with IL-8
siRNA. The invasion capacity of LNCaP-B1 cells transfected
with scrambled siRNA was unchanged from untreated B1 cells
(p ¼ 0.1); however, the inhibition of IL-8 using siRNA reduced
invasion by 73% 6 3%. Protein expression studies conﬁrmed
almost complete blockade of IL-8 expression (Fig. 4f).
Informed scheduling of the bioreductive drug AQ4N
increases the effectiveness of bicalutamide treatment
As we observed a large drop in tumour oxygenation following
bicalutamide treatment, we investigated the effect of adminis-
tering the bioreductive drug AQ4N with bicalutamide. We
used the oxygenation data obtained in Figure 1a to generate
an informed schedule of treatment, which consisted of 28 days
of bicalutamide treatment at 2 mg/kg/day with AQ4N (50 mg/
kg) given once via i.p. injection on Day 7. Mice treated with
bicalutamide-only demonstrated a reduction in tumour
growth up to Day 12/14 (Fig. 5a), after which the tumour vol-
ume rapidly increased. By Day 28, bicalutamide-only treated
tumours were the same size as vehicle-only controls. Treat-
ment with AQ4N combined with bicalutamide resulted in
LNCaP tumours that grew signiﬁcantly slower than those
treated with either vehicle-only or bicalutamide. Mice treated
with vehicle-only reached double their treatment starting vol-
ume at 11.4 6 0.5 days (Fig. 5b); however, this was not statisti-
cally different from those animals treated with vehicle and
AQ4N (p ¼ 0.82). Treatment with bicalutamide resulted in a
signiﬁcant tumour growth delay of 5.1 6 2.9 days (p ¼ 0.04).
Tumours treated with bicalutamide and AQ4N had the largest
tumour growth delay of 15.1 6 4.2 days (p ¼ 0.018).
Metastasis was assessed at 28 days in all groups to identify
if spread was inﬂuenced by treatment over the same time pe-
riod. The only site where metastatic cells were found was in
the lungs (Fig. 5c). Mice treated with bicalutamide had the
greatest bioluminescence (6.93 6 2.09  105 ph/sec; Fig. 5d);
however, this was not statistically different from those mice
treated with vehicle-only (5.875 6 2.34  105 ph/sec; p ¼
0.45). Mice treated with AQ4N-only had the least amount of
bioluminescence (1.99 6 1.64  105 ph/sec); however, this
was signiﬁcantly less than those treated with bicalutamide (p
¼ 0.002). Combining bicalutamide treatment with AQ4N
resulted in less bioluminescence than observed in bicaluta-
mide-treated animals (3.08 6 1.84  105 ph/sec; p ¼ 0.013).
Discussion
Bicalutamide is a widely used drug for the treatment of
locally advanced prostate cancer. Although sometimes it is
used as a single agent, often bicalutamide is combined with
Figure 2. The effect of daily bicalutamide treatment on the
vasculature of LNCaP tumour xenografts. An LNCaP tumour
fragment was implanted onto the dorsal skin fold of male Balb/c
SCID mice. (a) Tumour fragments were allowed to vascularise for 7
days. The vasculature was imaged using a confocal microscope by
i.v. injection of FITC-dextran 15 min prior to imaging. This was
carried out prior to commencement of treatment (Day 0) and after
7, 14 and 21 days in both vehicle- and bicalutamide-treated mice
(2 mg/kg/day). (b) Changes in area covered by blood vessels
during bicalutamide treatment. The results shown are mean 6 SE
(n ¼ 5); *p  0.05, **p  0.01 (two-way ANOVA).
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an lutenising hormone releasing hormone (LHRH) antagonist
and/or radiotherapy; usually, these modalities are used 2
weeks and 1–3 months, respectively, after the initiation of
bicalutamide treatment.20 Our study provides direct evidence
that immediately following initiation of a clinically relevant
bicalutamide treatment regimen, there is a collapse of the
tumour vasculature resulting in a profound decrease in
tumour oxygenation to a nadir of 0.05% oxygen (0.67 6 0.06
mmHg) on Day 7. Despite exposure to such profound hy-
poxia for 7–10 days, our data indicate that a proportion of
tumour cells were able to survive the onset of hypoxia and
through genetic selection/modiﬁcation were able to promote
tumour reoxygenation through stimulation of revascularisa-
tion (Fig. 2). This resulted in growth of a more malignant
androgen-insensitive tumour (Fig. 4).
Oxygenation readings in LNCaP xenografts demonstrated
that, with the exception of ﬁnasteride, a range of drugs that
interfere with androgen activity have the ability to signiﬁ-
cantly decrease tumour oxygenation within a very short time
(24 hr) of treatment initiation (Table 1). Previous studies
have shown that ﬁnasteride produces similar effects to bicalu-
tamide and ﬂutamide in reducing blood ﬂow and microvas-
cular density in normal rat prostate.11–13 These studies were
performed over a longer time frame than our experiments,
and therefore, it is feasible that the effects from ﬁnasteride
treatment take longer than 24 hr to appear, possibly due to
its different mechanism of action.
The initial biphasic oxygenation response seen in the
LNCaP xenograft model may also occur in patients; cur-
rently, there is no direct evidence of this. However, Ohlson et
al.21 reported a signiﬁcant drop in tumour cell proliferation
and an increase in apoptosis 3–4 days after castration of men
with prostate cancer. These parameters returned to normal
within 10 days. Although indirect, this study indicates a slow-
ing of growth and an increase in cell death at the same time
that our study shows the development of severe hypoxia fol-
lowing bicalutamide administration.
Although clinical measurements of tumour hypoxia fol-
lowing AD are conﬂicting, a study in 22 patients reported an
increase in prostate tumour oxygenation 30 days after andro-
gen withdrawal; however, there was considerable heterogene-
ity of response.22 Although this study seems contradictory to
Figure 3. The effect of daily bicalutamide treatment on gene expression in LNCaP tumour xenografts. Male Balb/c SCID mice bearing
tumours of 150–200 mm2 were treated with vehicle or bicalutamide (2 mg/kg/day) for 28 days. At various time points during treatment,
animals were killed and RNA was extracted from the tumour. QPCR was used to measure gene expression of (a) androgen receptor, (b)
VEGF, (c) IL-8 and (d) Bcl-2. The results shown are mean 6 SE of three pools of tumours; *p  0.05, **p  0.01, ***p  0.001 (two-way
ANOVA).
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our results, the earliest time point measured in the clinical
study was 30 days (ranging up to 135 days) after ADT was
initiated. It is therefore possible that an initial drop in pO2
was not detected due to the latent analysis of the tumours.
Additionally, a recent study in 14 patients showed that HIF1-
a protein expression dropped following castration23; however,
again the earliest time point examined was 1 month follow-
ing surgery. Conversely, Alonzi et al.24 studied patients with
prostate cancer who were treated with daily bicalutamide and
an additional depot injection of goserelin acetate (Zoladex) at
14 days. Using multiparameter MRI, they showed a drop in
blood ﬂow and features of increased hypoxia, which were
maintained throughout the 3-month follow-up.
It is worth noting that our experiments were carried out in
an animal model using LNCaP cells that are metastatic (albeit
weakly) and, therefore, may not be fully representative of the
clinical scenarios reported by Milosevic and Alonzi. The al-
ready metastatic nature of the model cell line may explain the
increased metastases following ADT in our system, which is
seemingly at odds with the clinical scenario using neoadjuvant
ADT prior to radiotherapy.25 However, patients do eventually
relapse and develop metastatic disease; the difference in time
frame between these observations in our animal model and
that observed in the clinic is a feature of preclinical models.
Consistent with the latent re-vascularisation of the
tumours observed >14 days post-ADT, we detected increased
expression of the pro-angiogenic factors VEGF and IL-8 in
excised tumour material. Furthermore, analysis of tumour
cells that were re-established from a tumour treated in vivo
with bicalutamide (LNCaP-B1) demonstrated evidence of
molecular and cellular adaptation to treatment. Cells exposed
to bicalutamide grew signiﬁcantly better in charcoal-stripped
medium than vehicle-treated tumour cells (LNCaP-V1),
showing that selection had occurred for cells that were less
dependent on androgen for growth. Additionally, increased
Bcl-2 mRNA was observed in both LNCaP tumours treated
with bicalutamide and bicalutamide-treated tumour cells re-
established in cell culture (LNCaP-B1). An increase in Bcl-2
Figure 4. Comparison of LNCaP tumour cells in ex vivo culture excised following 28 days of daily treatment with vehicle or bicalutamide.
Mice bearing LNCaP tumours were treated with either vehicle (LNCaP-V1) or bicalutamide (2 mg/kg/day) (LNCaP-B1) for 28 days. Cells were
re-established in culture after digestion with an enzyme cocktail. Comparison of expression levels of various genes measured by (a) QPCR
and (b) Western blotting. (c) Sensitivity of LNCaP-V1, LNCaP-B1 and LNCaP-B1 cells treated with Bcl-2 siRNA to treatment with docetaxel
was assessed using an XTT assay. The results shown are the mean 6 SE of three independent experiments. (d) Levels of Bcl-2 protein in
LNCaP-B1 cells following Bcl-2 siRNA treatment. (e) In vitro invasion of LNCaP-V1, LNCaP-B1 and LNCaP-B1 cells treated with IL-8 siRNA.
Data points are the mean 6 SE of 3 independent experiments. (f) Levels of IL-8 protein in LNCaP-B1 cells following siRNA IL-8 treatment.
***p  0.001 (two-tailed t-test).
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expression is a key molecular change in the progression of
prostate cancer26 and increases resistance to apoptosis. We
demonstrated that LNCaP-B1 cells were signiﬁcantly more
resistant to docetaxel than LNCaP-V1 cells; this was abol-
ished following siRNA Bcl-2 treatment. These results are of
clinical signiﬁcance as docetaxel is one of the drugs used in
patients who relapse with a castrate-resistant tumour after
bicalutamide treatment.27 A more comprehensive analysis of
gene expression may highlight other changes in gene expres-
sion that are associated with the development of bicalutamide
resistance and thus generate further novel targets for combi-
nation therapy with ADT.
A recent study8 in 247 patients treated with external beam
radiotherapy identiﬁed that tumour oxygenation measure-
ments were predictive of early biochemical failure, and Vergis
et al.9 showed that increased expression of HIF1 led to early
failure of both surgery and radiotherapy, indicating the im-
portance of hypoxic cells in the development of metastatic
disease. As we observed profound tumour hypoxia in our
animal model in the 2 weeks following bicalutamide treat-
ment, we investigated the effect of using the bioreductive
drug AQ4N in combination with bicalutamide on both pri-
mary tumour growth and on metastatic spread. In hypoxic
conditions, AQ4N is reduced to AQ4, a highly DNA-afﬁnic
cytotoxic compound that enhances the effects of both radia-
tion28,29 and chemotherapy.30,31 Supporting this approach is
the evidence that AQ4 levels correlate with Glut1 expression
in excised human tumours measured 24 hr after administra-
tion of AQ4N.32 We found that combining bicalutamide
treatment with a single dose of AQ4N administered on Day
7 resulted in increased primary tumour control and a reduc-
tion in the extensive metastasis observed with bicalutamide
alone. Interestingly, AQ4N alone is the most effective in
reducing metastasis. This can be explained by the predomi-
nant effect being exerted by AQ4N on the hypoxic cell com-
partment, that is, the more stress-resistant metastatic cells
(the tumour still grows as the oxic cells are less affected by
AQ4N). The combination of bicalutamide and AQ4N allows
Figure 5. The effect of combining bicalutamide and a bioreductive drug (AQ4N). Male SCID mice bearing tumours of 150–200 mm2 were
assigned to treatment groups: vehicle-only, vehicle þ AQ4N (50 mg/kg), bicalutamide only (2 mg/kg/day) and bicalutamide (2 mg/kg/day)
þ AQ4N (50 mg/kg). AQ4N was given by i.p. injection once on Day 7. (a) Tumour growth curves were obtained by measuring tumour
volume every 2 days until Day 28. The results represent the mean 6 SE (n ¼ 5). (b) Delay in the time for LNCaP tumours to reach double
their treatment volume. (c) Representative bioluminescence images of lungs from treated animals. (d) Quantification of bioluminescence.
The results shown are mean 6 SE (n ¼ 5).
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targeting of both cell compartments, thereby reducing growth
and extensive metastasis caused by bicalutamide alone. Our
study clearly demonstrates that selection of a targeting strat-
egy using the knowledge gained from the earlier experiments
can signiﬁcantly enhance the overall tumour response to
bicalutamide. It is also consistent with other evidence that
targeting hypoxic cells can reduce metastatic spread.33,34
Our study demonstrates proof-of-principle that targeting
hypoxic cells has a therapeutic beneﬁt in prostate cancer for
both primary tumour control and reducing metastatic dis-
ease. Although our study demonstrates the effectiveness of
treating androgen-sensitive cells, it may be advantageous to
target castrate-resistant disease using combination therapy
incorporating a bioreductive agent.
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